Oral Doxorubicin Lipid Nanoparticles Enhance Triple‐Negative Breast Cancer Therapy via Immune Activation and Reduced Cardiotoxicity

Documenti analoghi

• Sex Differences in Doxorubicin‐Induced Cardiotoxicity: Insights from Transcriptome Analysis
  di: Qingqing Su, et al.
  Pubblicazione: (2024)
• Enhanced Doxorubicin Cytotoxicity on Breast Cancer Spheroids by Aptamer Targeted Co‐Delivery with Hyaluronidase
  di: Murat Kavruk, et al.
  Pubblicazione: (2025)
• Microneedles‐Mediated Intradermal Delivery of Paclitaxel/Anti‐PD‐1 for Efficient and Safe Triple‐Negative Breast Cancer Therapy
  di: Jiachen Wang, et al.
  Pubblicazione: (2024)
• Correction to “Microneedles‐Mediated Intradermal Delivery of Paclitaxel/Anti‐PD‐1 for Efficient and Safe Triple‐Negative Breast Cancer Therapy”
  Pubblicazione: (2026)
• Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer
  di: Abhishek G. Sathe, et al.
  Pubblicazione: (2024)